The cellular response to cisplatin has also been assessed in an in vivo model of xenografts of BRCA1-methylated and unmethylated breast cancer cells, which showed that xenografts of BRCA1-methylated cells were significantly smaller following cisplatin treatment than xenografts of unmethylated cells [72]. This evidence concerns the gene BRCA1 and breast carcinoma.